Yaping Wu, Yingwen Wu, Guancheng Huang, Yemin Shi, Yanyan Zhang, XunXu, Juanfen Chu*
Department of Infection, YuyaoPeople’s Hospital, Yuyao, China
Objective: This paper evaluates the efficacy of adenosylmethionine in the treatment of cholestatic liver disease.
Method: Participants were divided into two groups. The observation group was given adenosyl methionine treatment, the standard liver protection treatment, and the clinical efficacy of the two groups was compared.
Results: After treatment, the TBIL, AST, ALT, PTA and other indicators were significantly better in the observation group than in the control group. The difference between the groups was statistically significant (P<0.05). The total effective rate was 81.82% in the control group and 93.94% in the observation group. The difference between the groups was statistically significant (P<0.05). The two groups were compared with reference to urinary colour, fatigue, stool colour, pruritus, hepatomegaly improvement rate, and the clinical symptoms of both groups were improved after treatment. Pruritus in the observation group was better than in the control group, and the data difference was statistically significant (P<0.05). The other data were not statistically significant (P>0.05).
Conclusion: Adenosylmethionine is effective in the treatment of patients with cholestatic liver disease, improving patients’ liver function and clinical symptoms. The treatment is therefore worthy of popularization.
Adenosine methionine, cholestasis, liver disease, adverse drug rate.